IMV101 / Immunofoco - LARVOL DELTA

A Study of IMV102 in Patients With Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov) - P1/2 | N=30 | Not yet recruiting | Sponsor: Suzhou Immunofoco Biotechnology Co., Ltd

New P1/2 trial • Hematological Malignancies • Multiple Myeloma • Oncology

A Phase I/IIa, Open-label, Single-center, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of IMV101 as a Single Agent in Subjects With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma (clinicaltrials.gov) - P1/2 | N=30 | Recruiting | Sponsor: Suzhou Immunofoco Biotechnology Co., Ltd

New P1/2 trial • B Cell Lymphoma • B Cell Non-Hodgkin Lymphoma • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Primary Mediastinal Large B-Cell Lymphoma

IMV101, a novel CD19-targeted In Vivo CAR T therapy exhibits potent efficacy and tolerable safety profiles in preclinical models (ASH 2025) - "IMV101 demonstrates high specificity of T cells transduction, potent in vitro and in vivo anti-tumor activity, effective expansion in peripheral blood of the in vivo generated CAR-T and a favorablesafety profile in murine models. This comprehensive data supports its further clinical development forboth B cell malignancies and autoimmune disease."

IO biomarker • Preclinical • Hematological Malignancies • Immunology • Infectious Disease • Pancreatic Cancer • CD34 • IFNG • IL10 • IL2 • IL6 • TNFA